Daniel Gaudet, MD, PhD (he/him/his)

Prof.
ECOGENE-21 QC and Université de Montréal, Canada

Poster(s):

• P069 - INITIAL RESULTS FROM THE PHASE 1B HEART-2 STUDY OF VERVE-102, AN INVESTIGATIONAL BASE EDITING MEDICINE DESIGNED TO INACTIVATE PCSK9 IN THE LIVER AND DURABLY LOWER LDL CHOLESTEROL
  Thursday, October 23, 2025

  6:00pm - 6:30pm ET

• P233 - COURSE OF PREGNANCIES AND OCCURRENCE OF ACUTE PANCREATITIS IN WOMEN WITH CHYLOMICRONEMIA
  Thursday, October 23, 2025

  5:30pm - 6:30pm ET

• P259 - FAMILIAL HYPERCHOLESTEROLEMIA IN CANADA: SEX DIFFERENCES IN DIAGNOSIS, MANAGEMENT AND OUTCOMES FROM THE FH CANADA REGISTRY
  Saturday, October 25, 2025

  12:15pm - 12:45pm ET

• P306 - HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN CANADA: 2025 REGISTRY UPDATE
  Friday, October 24, 2025

  5:30pm - 6:30pm ET

• P320 - LONG-TERM (>15 YEARS) MONITORING OF PATIENTS WITH PERSISTENT CHYLOMICRONEMIA TREATED WITH ALIPOGENE TIPARVOVEC LPL GENE-REPLACEMENT THERAPY WHO SUBSEQUENTLY RECEIVED PRECISION TG-LOWERING THERAPEUTICS
  Saturday, October 25, 2025

  12:30pm - 1:30pm ET

• P330 - PERFORMANCE OF THREE DIAGNOSIS SYSTEMS FOR THE DIFFERENTIAL DIAGNOSIS OF PERSISTENT CHYLOMICRONEMIA PHENOTYPES
  Saturday, October 25, 2025

  12:30pm - 1:30pm ET

• P343 - SEX DIFFERENCES IN BASELINE CHARACTERISTICS AND RESPONSE TO EVINACUMAB AMONG PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
  Saturday, October 25, 2025

  12:30pm - 1:30pm ET

• P358 - COMPLEX AORTIC VALVE AND AORTIC DISEASE IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: THE CANADIAN HOFH REGISTRY
  Friday, October 24, 2025

  5:30pm - 6:30pm ET